Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
VACCINEX, INC. (VCNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/12/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/11/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
10/04/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Attention: Mr. Maurice Zauderer, Ph.D. 1895 Mount Hope Avenue Rochester, New York 14620",
"FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: October 3, 2023 Issue Date: October 3, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full , but not thereafter, to subscribe for and purchase from Vaccinex, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwi...",
"FORM OF COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: October 3, 2023 Issue Date: October 3, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 3, 2023 and on or prior to 5:00 p.m. on October 3, 2028 , but not thereafter, to subscribe for and purchase from Vaccinex, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein ...",
"Form of Securities Purchase Agreement"
10/02/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
09/29/2023 EFFECT Form EFFECT - Notice of Effectiveness:
09/28/2023 S-1MEF Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]:
09/27/2023 8-K Quarterly results
09/26/2023 SC 13D/A Zauderer Maurice reports a 10.8% stake in VACCINEX, INC.
08/22/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Stock Purchase Agreement by and between the Company and the Investors",
"Registration Rights Agreement by and between the Company and the Investors"
08/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
07/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/25/2023 SC 13D/A FCMI Parent Co. reports a 46.3% stake in VACCINEX, INC.
05/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Hogan Lovells US LLP"
05/19/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/15/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Stock Purchase Agreement, by and between the Company and the Investors (as defined therein)"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/06/2023 ARS Form ARS - Annual Report to Security Holders:
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 SC 13D/A FCMI Parent Co. reports a 42.8% stake in VACCINEX, INC.
04/03/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/03/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Stock Purchase Agreement by and between the Company and the Investors (as defined therein)",
"Stock Purchase Agreement by and between the Company and the Investors (as defined therein)"
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis"
02/01/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/01/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/24/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/29/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/28/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy